[Prospective observational study of insulin detemir in patients with poorly controlled type 2 diabetes mellitus initiating insulin therapy for the first time (SOLVE Study)].
CONCLUSIONS: In this cohort of patients with type 2 diabetes mellitus receiving newly initiated insulin therapy, once-daily detemir improved the glycemic control, with low incidence of hypoglycemia and a significant reduction of the weight.
PMID: 26054893 [PubMed - as supplied by publisher] (Source: Atencion Primaria)
Source: Atencion Primaria - June 5, 2015 Category: Primary Care Authors: Orozco-Beltrán D, Artola-Menéndez S Tags: Aten Primaria Source Type: research
Long-term outcomes of analogue insulin compared with NPH for patients with type 2 diabetes mellitus.
CONCLUSIONS: We found no consistent difference in long-term health outcomes when comparing use of long-acting insulin analogues and NPH insulin. The higher cost of analogue insulin without demonstrable clinical benefit raises questions of its cost-effectiveness in the treatment of patients with diabetes.
PMID: 26014311 [PubMed - in process] (Source: The American Journal of Managed Care)
Source: The American Journal of Managed Care - May 30, 2015 Category: Health Management Authors: Prentice JC, Conlin PR, Gellad WF, Edelman D, Lee TA, Pizer SD Tags: Am J Manag Care Source Type: research
The weight‐sparing effect of insulin detemir: a consequence of central nervous system‐mediated reduced energy intake?
Abstract
Insulin therapy is often associated with adverse weight gain. This is due, at least in part, to changes in energy balance and insulin's anabolic effects. Adverse weight gain increases the risk of poor macrovascular outcomes in people with diabetes and should therefore be mitigated if possible. Clinical studies have shown that insulin detemir, a basal insulin analogue, exerts a unique weight‐sparing effect compared with other basal insulins. To understand this property, several hypotheses have been proposed. These explore the interplay of efferent and afferent signals between muscles, brain, liver, renal and adip...
Source: Diabetes, Obesity and Metabolism - May 13, 2015 Category: Endocrinology Authors: D. Russell‐Jones, T. Danne, K. Hermansen, K. Niswender, K. Robertson, N. Thalange, J. R. Vasselli, B. Yildiz, H. U. Häring Tags: Review Article Source Type: research
Glucose‐lowering effect and glycaemic variability of insulin glargine, insulin detemir and insulin lispro protamine in people with type 1 diabetes
ConclusionsThe results suggest that insulin lispro protamine and glargine are more effective than detemir in reducing glycaemic variability and improving glycaemic control in people with type 1 diabetes. Insulin lispro protamine seems to lead to fewer hypoglycaemic events than other insulin regimens. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - April 2, 2015 Category: Endocrinology Authors: G. Derosa, I. Franzetti, F. Querci, D. Romano, A. D'Angelo, P. Maffioli Tags: ORIGINAL ARTICLE Source Type: research
The use of insulin detemir during pregnancy: a safety evaluation
Expert Opinion on Drug Safety, Ahead of Print. (Source: Expert Opinion on Drug Safety)
Source: Expert Opinion on Drug Safety - March 3, 2015 Category: Drugs & Pharmacology Tags: article Source Type: research
Pen Needle Preference in a Population of Canadians with Diabetes: Results from a Recent Patient Survey
Conclusions In patients with insulin-treated type 2 diabetes with a mean single-injection volume dose of basal insulin of 50.2 units, the 5 mm needle was generally preferred over the 8 mm needle. The shorter needle was more comfortable and easier to use while being equally effective in delivering insulin. (Source: Canadian Journal of Diabetes)
Source: Canadian Journal of Diabetes - February 26, 2015 Category: Endocrinology Source Type: research
Glucose‐lowering effect and glycemic variability of insulin glargine, insulin detemir, and insulin lispro protamine in people with type 1 diabetes
Conclusionsinsulin lispro protamine and glargine seems to be more effective than detemir in reducing glycemic variability and improving glycemic control in people with type 1 diabetes. Insulin lispro protamine seems to give less hypoglycemic events than other insulin regimens. (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - February 19, 2015 Category: Endocrinology Authors: Giuseppe Derosa, Ivano Franzetti, Fabrizio Querci, Davide Romano, Angela D'Angelo, Pamela Maffioli Tags: Original Paper Source Type: research
Treatment persistence after initiating basal insulin in type 2 diabetes patients: A primary care database analysis
In the long run insulin will be required in most type 2 diabetic patients to maintain glycemic control due to the progressive beta cell dysfunction [1]. Current guidelines from the American Diabetes Association and the European Association for the Study of Diabetes note that the majority of patients with type 2 diabetes requiring insulin therapy can be successfully treated with basal insulins [2]. Either intermediate-acting (neutral protamine Hagedorn [NPH]) or long-acting analogs such as insulin glargine or insulin detemir may be used [2]. (Source: Primary Care Diabetes)
Source: Primary Care Diabetes - February 17, 2015 Category: Primary Care Authors: Stefan Pscherer, Engels Chou, Franz-Werner Dippel, Wolfgang Rathmann, Karel Kostev Tags: Original research Source Type: research
A randomized controlled trial of liraglutide versus insulin detemir plus sitagliptin: Effective switch from intensive insulin therapy to the once-daily injection in patients with well-controlled type 2 diabetes.
This study aimed to compare the efficacy and safety of liraglutide versus insulin detemir plus sitagliptin in Japanese patients with type 2 diabetes treated with basal-bolus insulin regimen. In this multicenter, open-label trial, 90 patients whose diabetes had been controlled well or moderately [glycosylated hemoglobin (HbA1c) ≤ 7.3%] with basal-bolus insulin regimen were randomly assigned to a liraglutide group or a detemir group and were followed up for 24 weeks. The primary end point was HbA1c change from baseline to 24 weeks. Of the 90 enrolled patients, 82 completed this trial. At 24 weeks, the mean changes in HbA1c...
Source: The Journal of Clinical Pharmacology - February 13, 2015 Category: Drugs & Pharmacology Authors: Inoue Y, Nakamura A, Kondo Y, Hamano K, Satoh S, Terauchi Y Tags: J Clin Pharmacol Source Type: research
Insulin detemir is transported from blood to cerebrospinal fluid and has prolonged central anorectic action relative to NPH insulin.
Abstract
Insulin detemir (DET) reduces glycemia comparably to other long-acting insulin formulations, but causes less weight-gain. Insulin-signaling in the brain is catabolic, reducing food intake. We hypothesized that DET reduces weight-gain, relative to other insulins, due to increased transport into the central nervous system and/or increased catabolic action within the brain. Transport of DET and NPH insulin (NPH) into the cerebrospinal fluid (CSF) was compared over several hours and following the administration of different doses peripherally in rats. DET and NPH had comparable saturable, receptor-med...
Source: Diabetes - February 9, 2015 Category: Endocrinology Authors: Begg DP, May AA, Mul JD, Liu M, D'Alessio DA, Seeley RJ, Woods SC Tags: Diabetes Source Type: research
Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes
Insulin degludec (IDeg) once‐daily was compared with insulin detemir (IDet) once‐ or twice‐daily, with prandial insulin aspart in a treat‐to‐target, randomized controlled trial in children 1–17 yr with type 1 diabetes, for 26 wk (n = 350), followed by a 26‐wk extension (n = 280). Participants were randomized to receive either IDeg once daily at the same time each day or IDet given once or twice daily according to local labeling. Aspart was titrated according to a sliding scale or in accordance with an insulin:carbohydrate ratio and a plasma glucose correction factor. Randomization was age‐strati...
Source: Pediatric Diabetes - February 1, 2015 Category: Endocrinology Authors: Nandu Thalange, Larry Deeb, Violeta Iotova, Tomoyuki Kawamura, Georgeanna Klingensmith, Areti Philotheou, Janet Silverstein, Stefano Tumini, Ann‐Marie Ocampo Francisco, Ona Kinduryte, Thomas Danne Tags: Original Article Source Type: research
Insulin detemir does not cross the human placenta.
PMID: 25614695 [PubMed - in process] (Source: Diabetes Care)
Source: Diabetes Care - January 28, 2015 Category: Endocrinology Authors: Suffecool K, Rosenn B, Niederkofler EE, Kiernan UA, Foroutan J, Antwi K, Ribar A, Bapat P, Koren G Tags: Diabetes Care Source Type: research
Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus
Conclusion
For the majority of examined efficacy and safety outcomes, IGlar use in T2DM patients was superior or non-inferior to the alternative insulin treatment options. (Source: Acta Diabetologica)
Source: Acta Diabetologica - January 14, 2015 Category: Endocrinology Source Type: research
daf-16 /FOXO and glod-4 /glyoxalase-1 are required for the life-prolonging effect of human insulin under high glucose conditions in Caenorhabditis elegans
Conclusions/interpretation
Human insulin and its analogues prevent the reduction in lifespan and neuronal damage caused by HG conditions. The effect of human insulin is mediated by a daf-2/insulin receptor and daf-16/FOXO-dependent pathway and is mediated by upregulation of detoxifying mechanisms. (Source: Diabetologia)
Source: Diabetologia - January 10, 2015 Category: Endocrinology Source Type: research
Effect of Subcutaneous Insulin Detemir on Glucose Flux and Lipolysis during Hyperglycaemia in People with Type 1 Diabetes
ConclusionsThe results are also consistent with the hypothesis that detemir has a lesser effect on the periphery, as evidenced by a lesser effect on peripheral glucose uptake at specific glucose concentrations (Source: Diabetes, Obesity and Metabolism)
Source: Diabetes, Obesity and Metabolism - January 1, 2015 Category: Endocrinology Authors: Roselle A. Herring, Fariba Shojaee‐Moradie, A.Margot Umpleby, Richard Jones, Nicola Jackson, David L. Russell‐Jones Tags: ORIGINAL ARTICLE Source Type: research
